Whipplewood Advisors LLC Acquires 4,132 Shares of CRISPR Therapeutics AG $CRSP

Whipplewood Advisors LLC boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 82,640.0% in the second quarter, HoldingsChannel reports. The firm owned 4,137 shares of the company’s stock after buying an additional 4,132 shares during the quarter. Whipplewood Advisors LLC’s holdings in CRISPR Therapeutics were worth $201,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in CRSP. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in CRISPR Therapeutics by 182.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company’s stock worth $66,452,000 after purchasing an additional 1,262,560 shares in the last quarter. ARK Investment Management LLC grew its position in CRISPR Therapeutics by 13.3% in the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock worth $345,929,000 after purchasing an additional 1,192,336 shares in the last quarter. Millennium Management LLC grew its position in CRISPR Therapeutics by 6,769.1% in the 1st quarter. Millennium Management LLC now owns 583,733 shares of the company’s stock worth $19,864,000 after purchasing an additional 575,235 shares in the last quarter. McElhenny Sheffield Capital Management LLC bought a new stake in CRISPR Therapeutics in the 2nd quarter worth about $6,615,000. Finally, Orbis Allan Gray Ltd grew its position in CRISPR Therapeutics by 5.9% in the 1st quarter. Orbis Allan Gray Ltd now owns 1,562,932 shares of the company’s stock worth $53,187,000 after purchasing an additional 86,813 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 50,895 shares of the company’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the sale, the chief executive officer directly owned 254,201 shares in the company, valued at approximately $17,262,789.91. This represents a 16.68% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of the company’s stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the sale, the general counsel owned 83,402 shares in the company, valued at $5,554,573.20. The trade was a 1.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,213 shares of company stock worth $3,810,458 over the last 90 days. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Stock Up 0.6%

CRISPR Therapeutics stock opened at $67.61 on Monday. The company has a market capitalization of $6.15 billion, a P/E ratio of -12.45 and a beta of 1.84. The firm has a 50 day moving average price of $61.62 and a 200-day moving average price of $51.52. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.29) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.18. The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. CRISPR Therapeutics’s revenue was up 72.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.49) EPS. Equities analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on CRSP. Royal Bank Of Canada upped their price objective on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a “sector perform” rating in a research report on Tuesday, August 5th. Wells Fargo & Company set a $75.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Friday. Zacks Research raised shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Finally, Bank of America increased their target price on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Ten equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $72.59.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.